RxDoctor Payments Data

Angelo Pulgiano, MD

Internal Medicine · Riverton, UTNPI 1952322836

Payments from drug & device makers

$1,732in general payments, 2019–2025

Across 82 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$371
  • Lilly USA, LLC$198
  • AstraZeneca$168
  • Amgen$153
  • Novo Nordisk$119
  • Astellas Pharma US Inc$113
  • plus $611 from 20 others

What the payments were for

  • Food & beverage$1,732100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,732 in reported general payments places this provider in the 75th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah

Medicare billing

Part B allowed, 2024
$58,514
Medicare patients
107
Services billed
910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide125$159,215
JardianceEmpagliflozin69$87,131
OzempicSemaglutide46$75,864
EliquisApixaban41$50,900
ProliaDenosumab23$38,587
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$31,323
FarxigaDapagliflozin Propanediol25$31,114
MyrbetriqMirabegron22$19,251
JanuviaSitagliptin Phosphate13$13,626
Tresiba Flextouch U-200Insulin Degludec14$9,117
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$4,822
Gabapentin88$2,412
Levothyroxine Sodium229$2,278
Atorvastatin Calcium235$2,269
Rosuvastatin Calcium166$2,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$198$159,215125 claims
Novo NordiskOzempic$119$75,86446 claims
PfizerEliquis$34$50,90041 claims
AmgenProlia$153$38,58723 claims
GSKTrelegy Ellipta$55$31,32336 claims
AstraZenecaFarxiga$168$31,11425 claims
Astellas Pharma US IncMyrbetriq$113$19,25122 claims
MerckJanuvia$19$13,62613 claims
Almatica Pharma LLCSertraline Hcl$20$1,433134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 496 internal medicine providers in Utah.

Other internal medicine in Riverton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →